Latest news
Sarepta Therapeutics, Inc. Revenue Breakdown – BX:AB3A - TradingViewTradingView · Sun, 09 Aug 2026 01:01:58 GMTSarepta's Q2 Earnings & Sales Beat Estimates, '26 Outlook Updated - TradingViewTradingView · Thu, 06 Aug 2026 18:05:00 GMTSRPT: Q2 profitability and cash growth support narrowed 2026 guidance amid stable Duchenne demand - TradingViewTradingView · Wed, 05 Aug 2026 23:23:15 GMTSarepta Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary - TradingViewTradingView · Wed, 05 Aug 2026 21:01:54 GMTSRPT: Q2 2026 delivered profitability, strong cash flow, and narrowed FY 2026 revenue guidance - TradingViewTradingView · Wed, 05 Aug 2026 20:47:17 GMTSRPT: Q2 2026 delivered operating profitability on $328.7M revenue, but sales fell 34% year-over-year - TradingViewTradingView · Wed, 05 Aug 2026 20:11:27 GMTSarepta Therapeutics 2Q 2026: Revenue $328.7M, EPS $(0.05) — 10-Q Summary - TradingViewTradingView · Wed, 05 Aug 2026 20:11:00 GMTSRPT: Q2 2026 revenues dropped 34% year-over-year as ELEVIDYS sales declined sharply after safety events - TradingViewTradingView · Wed, 05 Aug 2026 20:09:40 GMT